Soligenix, Inc. (SNGX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SNGX
- Company Soligenix, Inc.
- Price $0.42
- Changes Percentage -4.69
- Change -0.0208
- Day Low $0.42
- Day High $0.47
- Year High $6.23
- Year Low $0.28
- Market Cap $4,979,163
- Price Avg 50 EMA (D) $0.84
- Price Avg 200 EMA (D) $1.46
- Exchange NASDAQ
- Volume 6,524,287
- Average Volume 7,039,145
- Open $0.45
- Previous Close $0.44
- EPS -1.45
- PE -0.33
- Earnings Announcement 2026-08-07 12:00:00
- Shares Outstanding $10,306,692
Company brief: SOLIGENIX, INC. (SNGX )
- Healthcare
- Biotechnology
- Dr. Christopher J. Schaber Ph.D.
- https://www.soligenix.com
- US
- N/A
- 04-04-1994
- US8342235053
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.